Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.42 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.42 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.42 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | WNT3 | P56703 | 1/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615993 | 0.84 | SFRP1 (0.55) | HSD11B1WNT3SFRP1 | |
| SCHEMBL4616786 | 0.81 | HSD11B1 (0.49) | HSD11B1HTR2CHTR2BSLC22A12ABCC9 | |
| SCHEMBL4616832 | 0.81 | HSD11B1 (0.45) | HSD11B1HTR2CHTR2BABCC9ABCC8 | |
| SCHEMBL4617928 | 0.78 | KMT2A (0.54) | HSD11B1HTR2CHTR2BABCC9ABCC8 | |
| SCHEMBL4617061 | 0.77 | HSD11B1 (0.54) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL65955 | 0.74 | MEN1 (0.56) | HSD11B1SLC22A12CYP2C9 | |
| SCHEMBL29500393 | 0.74 | MEN1 (0.56) | HSD11B1SLC22A12CYP2C9 | |
| SCHEMBL6101134 | 0.74 | SFRP1 (0.60) | WNT3SFRP1 | |
| SCHEMBL27713242 | 0.74 | SLC22A12 (0.34) | HSD11B1SLC22A12WNT3SFRP1 | |
| SCHEMBL4616747 | 0.73 | PKM (0.53) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | HSD11B1 205/4885HTR2C 3668/4885HTR2B 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.